losartan / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 233 Diseases   125 Trials   125 Trials   3075 News 


«12345678910111213...4142»
  • ||||||||||  losartan / Generic mfg.
    Journal, Metastases:  Tackling Losartan Contamination: The Promise of Peroxymonosulfate/Fe(II) Advanced Oxidation Processes. (Pubmed Central) -  May 25, 2024   
    The results revealed that Losartan degradation reached a significant level of 64%, underscoring the efficacy of PMS/Fe(II) AOP techniques as promising strategies for the removal of Losartan from water systems. This research not only enriches our understanding of pollutant degradation mechanisms, but also paves the way for the development of sustainable water treatment technologies, specifically targeting the removal of pharmaceutical contaminants from aquatic environments.
  • ||||||||||  aganirsen (GS 101) / Gene Signal
    Review, Journal:  Available Therapeutic Options for Corneal Neovascularization: A Review. (Pubmed Central) -  May 25, 2024   
    These multifaceted approaches underscore the corneal neovascularization management complexity and highlight ideas for enhancing therapeutic outcomes. Furthermore, the importance of combination therapies and the need for further research to develop specific inhibitors while considering their therapeutic efficacy and potential adverse effects are discussed.
  • ||||||||||  losartan / Generic mfg.
    Preclinical, Journal:  Mitochondrial KATP channel-mediated autophagy contributes to angiotensin II-induced vascular dysfunction in mice. (Pubmed Central) -  May 23, 2024   
    Our results support a model of DEE75 resulting from reduced NeuroD2 activity during vertebrate brain development, and indicate that a leaky blood-brain barrier contributes to epileptogenesis. Our present findings evidence that mitochondrial KATP channel-mediated autophagy contributes to Ang II-induced vascular dysfunction, development of hypertension, and atherosclerosis.
  • ||||||||||  Review, Journal:  Drugs for hypertension. (Pubmed Central) -  May 21, 2024   
    This study shows that broad screening approaches like this are applicable to the analysis of drug products and can be an important enhancement of the quality assurance of medicinal products. No abstract available
  • ||||||||||  losartan / Generic mfg., atenolol / Generic mfg., bisoprolol / Generic mfg.
    Marfan syndrome in children: large, single centre experience on management and outcome (Science Box 5 - Research Gateway) -  May 14, 2024 - Abstract #ESC2024ESC_1159;    
    Our data confirm a decrease in SOV z-score with chemoprophylaxis in a real-world cohort. This is in line with current evidence and corroborates clinical practice.
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Impact of plasma from patients with severe aortic stenosis on valvular endothelial cells (Station 5 - Research Gateway) -  May 14, 2024 - Abstract #ESC2024ESC_57;    
    This adverse impact is mediated by multiple mechanisms, including activation of the AT1R/NADPH oxidase/SGLT2 pathway, upregulation of pro-inflammatory cytokines, and activation of PAR. FXa plays a pivotal role by promoting oxidative stress in VECs and contributing to valvular endothelial dysfunction.
  • ||||||||||  TRV027 / Trevena, irbesartan/propagermanium (DMX-200) / Dimerix
    Journal:  Investigation of Strategies to Block Downstream Effectors of AT1R-Mediated Signalling to Prevent Aneurysm Formation in Marfan Syndrome. (Pubmed Central) -  May 11, 2024   
    Our results confirm that while losartan effectively halts aneurysm formation in Fbn1C1041G/+ MFS mice, neither TRV027 alone nor any of the other compounds combined with lower doses of losartan demonstrate a notable impact on aneurysm advancement. It appears that complete blockade of AT1R function, achieved by administrating a high dosage of losartan, may be necessary for inhibiting aneurysm progression in MFS.
  • ||||||||||  losartan / Generic mfg.
    Preclinical, Journal:  Angiotensin II Directly Increases Endothelial Calcium and Nitric Oxide in Kidney and Brain Microvessels In (Pubmed Central) -  May 10, 2024   
    The present study directly visualized angiotensin II-induced increases in VEC [Ca2+]i and NO production that serve to counterbalance agonist-induced vasoconstriction and maintain residual organ blood flow. These direct and endothelium-specific angiotensin II effects were blunted in disease conditions and linked to endothelial dysfunction and the development of vascular pathologies.
  • ||||||||||  torasemide / Generic mfg.
    PK/PD data, Review, Journal:  A Systematic Critical Review of Clinical Pharmacokinetics of Torasemide. (Pubmed Central) -  May 9, 2024   
    These direct and endothelium-specific angiotensin II effects were blunted in disease conditions and linked to endothelial dysfunction and the development of vascular pathologies. The current review summarizes all available PK parameters of torasemide that may be beneficial for avoiding drug-drug interactions in subjects with renal and hepatic dysfunction and for predicting doses in patients with different diseases.
  • ||||||||||  losartan / Generic mfg., perindopril arginine / Generic mfg.
    Trial completion date, Trial primary completion date:  ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension (clinicaltrials.gov) -  May 8, 2024   
    P2,  N=213, Active, not recruiting, 
    The current review summarizes all available PK parameters of torasemide that may be beneficial for avoiding drug-drug interactions in subjects with renal and hepatic dysfunction and for predicting doses in patients with different diseases. Trial completion date: May 2024 --> Sep 2024 | Trial primary completion date: May 2024 --> Sep 2024
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Safe Use of SGLT2-Inhibitor in a Pancreas Transplant Recipient with a Functioning Graft and Chronic Kidney Disease: A Case Report (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_962;    
    To our knowledge, this is the first report of SGLT2-I use in a pancreas transplant recipient with a functioning graft. Given the overwhelming kidney, metabolic, and cardiovascular benefits of SGLT2-I, it is important to describe its safety in different patient populations, including solid-organ transplant recipients with clinical indications for SGLT2-inhibition.
  • ||||||||||  losartan / Generic mfg.
    Enrollment closed:  Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan (clinicaltrials.gov) -  Apr 16, 2024   
    P1/2,  N=68, Active, not recruiting, 
    SSR can improve renal hypoxia to attenuate renal injury in 5/6 (A/I) rats of CKD. Recruiting --> Active, not recruiting
  • ||||||||||  Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  WARRIOR: Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (clinicaltrials.gov) -  Apr 11, 2024   
    P4,  N=2476, Active, not recruiting, 
    Trial primary completion date: Apr 2024 --> Apr 2025 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024 | Recruiting --> Active, not recruiting | N=4422 --> 2476
  • ||||||||||  losartan / Generic mfg.
    Review, Journal, Stroma:  Two-phase mechanism in the treatment of corneal stromal fibrosis with topical losartan. (Pubmed Central) -  Apr 3, 2024   
    Eventually, keratocytes reemerge in the previously fibrotic stromal tissue to fine-tune the collagens and other ECM components and maintain the normal structure of the corneal stroma. The efficacy of losartan in the prevention and treatment of corneal fibrosis suggests that it acts as a surrogate for the EBM, by suppressing TGF beta-directed scarring of the wounded corneal stroma, until control over TGF beta action is re-established by a healed EBM, while also supporting regeneration of the EBM by allowing corneal fibroblasts to occupy the subepithelial stroma in the place of myofibroblasts.
  • ||||||||||  losartan / Generic mfg.
    Journal:  Factors Associated with the Development of Chronic Kidney Disease in Patients with Arterial Hypertension. (Pubmed Central) -  Apr 3, 2024   
    The efficacy of losartan in the prevention and treatment of corneal fibrosis suggests that it acts as a surrogate for the EBM, by suppressing TGF beta-directed scarring of the wounded corneal stroma, until control over TGF beta action is re-established by a healed EBM, while also supporting regeneration of the EBM by allowing corneal fibroblasts to occupy the subepithelial stroma in the place of myofibroblasts. The average age for 2015 was 69.79
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Preclinical, Journal:  Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists. (Pubmed Central) -  Apr 1, 2024   
    A literature survey indicated that few previously evaluated compounds (e.g., latanoprost, timolol, pilocarpine, brimonidine, dorzolamide, cromakalim analog (CKLP1), losartan, tissue plasminogen activator, trans-resveratrol, sodium 4-phenyl acetic acid, etc.) in various animal models of steroid-induced OHT were able to match the effectiveness of misoprostol, PF-04217329 or butaprost. Since a common feature of the latter compounds is their relatively high affinity and potency at the EP2-PG receptor sub-type, which activates the production of intracellular cAMP in target cells, our studies suggest that drugs selective for the EP2-PG receptor may be suited to treat corticosteroid-induced OHT.
  • ||||||||||  Avastin (bevacizumab) / Roche, Sirturo (bedaquiline) / J&J, Pharmstandard
    Preclinical, Journal:  Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits. (Pubmed Central) -  Mar 30, 2024   
    RNA sequencing analysis of HDT-treated lung and granuloma tissues implicates up-regulated antimicrobial peptide and proinflammatory gene expression by ciliated epithelial airway cells as a putative mechanism of the observed antitubercular benefits in the absence of chemotherapy. These findings demonstrate that bevacizumab and losartan are well-tolerated stroma-targeting HDTs, normalize the granuloma microenvironment, and improve TB outcomes, providing the rationale to clinically test this combination in TB patients.
  • ||||||||||  losartan / Generic mfg.
    Unraveling Immune Profile Changes in Losartan-Treated COVID-19 Patients Using Mass Cytometry (Exhibit Hall F1; Poster Board Number: B1016) -  Mar 29, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_981;    
    The enhanced adaptive immunity was observed in COVID-19 patients exhibiting favorable outcomes. Additional investigation with larger cohorts and a placebo control is underway to delineate the observed trend's relevance to susceptibility factors and clinical outcomes.
  • ||||||||||  losartan / Generic mfg.
    Trial completion date, Trial primary completion date:  HTN: Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design (clinicaltrials.gov) -  Mar 27, 2024   
    P=N/A,  N=57600, Active, not recruiting, 
    In the logistic regression model, independent factors associated with reaching SUA target were febuxostat use (OR 11.40, 95% CI 5.10 Trial completion date: Mar 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
  • ||||||||||  losartan / Generic mfg.
    Biomarker, Journal, Tumor microenvironment, Lipid Nanoparticle:  Ionizable Lipid Nanoparticle-Mediated TRAIL mRNA Delivery in the Tumor Microenvironment to Inhibit Colon Cancer Progression. (Pubmed Central) -  Mar 23, 2024   
    Next, we investigated the ability of LNP-TRAIL to inhibit colon cancer progression in vivo in combination with a TME normalization approach using Losartan (Los) or angiotensin 1-7 (Ang(1-7)) to reduce vascular compression and deposition of extracellular matrix in mice...Together, our data demonstrate the potential of the LNP to deliver TRAIL mRNA to the TME and to induce tumor cell death, especially when combined with TME normalization. Therefore, these findings provide important insights for the development of novel therapeutic strategies for the immunotherapy of solid tumors.
  • ||||||||||  carvedilol / Generic mfg., losartan / Generic mfg.
    Could not hide any longer: A case of Primary Hyperaldosteronism () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_899;    
    However, PA remains under recognized by clinicians. It is estimated that PA is present in 1 in 550 patients with HTN in the United States but rarely diagnosed, thus highlighting the vast degree of PA underdiagnosis.
  • ||||||||||  Unexplained CKD With Unexpected Finding of Liddle Syndrome () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_778;    
    LS was not initially considered as a differential diagnosis, particularly due to the absence of low aldosterone and renin levels that are usually suggestive of LS. The genetic testing that revealed the mutation was surprising, but this finding combined with the patient's impressive response to the addition of amiloride supported the ultimate diagnosis of LS as an explanation for his long-standing HTN and development of CKD.
  • ||||||||||  losartan / Generic mfg.
    A case of FAN1- Associated Karyomegalic Interstitial Nephritis () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_683;    
    Serum creatinine can be deceiving low on presentation, a high index of suspicion and low threshold of biopsy can make the diagnosis. The FAN1 gene is involved in the DNA damage response pathway.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    A Turn of the Page in a Thrombotic Microangiopathy Case () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_610;    
    The FAN1 gene is involved in the DNA damage response pathway. He received eculizumab therapy with improvement in platelet count to 130,000/
  • ||||||||||  A Surgical Odyssey in Primary Aldosteronism Management () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_492;    
    This case underscores the importance of screening individuals with hypertension and hypokalemia for secondary causes. AVS plays a pivotal role in determining the suitability of surgical intervention for patients with PA, particularly in cases of unilateral adrenal hyperplasia, where surgery can be curative.